Improving drug tolerability is the cornerstone of our research strategy
Giiant Pharma inc. is a Montreal-based company founded by former Merck Frosst scientists Dr. Elizabeth Kwong and Dr. Bernard Côté. Strong from more than 20 years of experience in the field of industrial pharmaceutical research, we have put together a discovery platform where improving drug tolerability is the cornerstone of our strategy.
Treatment-associated side effects such as nausea, dry mouth, headache, diarrhea/constipation or mood change have a significant impact on quality of life and treatment adherence. In the context of a life-long medical condition such as IBD, addressing these potential issues becomes even more critical.
Why delivering a drug to your brain, heart, liver, skin, muscle and others when only a segment of your intestine is affected? Is it possible to benefit from an anti-inflammatory treatment without suffering the strong immunosuppression from prednisone, azathioprine or injectable biologics? At Giiant Pharma we believe that this is possible with a technology that confines the drug to the sick organ.